ES2186375T3 - Levosimendano para tratar el hipertension pulmonar. - Google Patents

Levosimendano para tratar el hipertension pulmonar.

Info

Publication number
ES2186375T3
ES2186375T3 ES99931313T ES99931313T ES2186375T3 ES 2186375 T3 ES2186375 T3 ES 2186375T3 ES 99931313 T ES99931313 T ES 99931313T ES 99931313 T ES99931313 T ES 99931313T ES 2186375 T3 ES2186375 T3 ES 2186375T3
Authority
ES
Spain
Prior art keywords
pulmonary hypertension
levosimendano
treat
propanedinitrile
hydrazono
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99931313T
Other languages
English (en)
Inventor
Lasse Lehtonen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Oyj
Original Assignee
Orion Oyj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Oyj filed Critical Orion Oyj
Application granted granted Critical
Publication of ES2186375T3 publication Critical patent/ES2186375T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

Uso de (-)-[[4-(1,4,5,6-tetrahidro-4-metil-6-oxo- 3-piridazinil)fenil]hidrazono]propanodinitrilo o una sal farmacéuticamente aceptable del mismo en la fabricación de un medicamento para el tratamiento de la hipertensión pulmonar.
ES99931313T 1998-06-25 1999-06-18 Levosimendano para tratar el hipertension pulmonar. Expired - Lifetime ES2186375T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI981473A FI981473A (fi) 1998-06-25 1998-06-25 Menetelmä pulmonaalihypertension hoitamiseksi

Publications (1)

Publication Number Publication Date
ES2186375T3 true ES2186375T3 (es) 2003-05-01

Family

ID=8552079

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99931313T Expired - Lifetime ES2186375T3 (es) 1998-06-25 1999-06-18 Levosimendano para tratar el hipertension pulmonar.

Country Status (24)

Country Link
US (1) US6462045B1 (es)
EP (1) EP1089737B1 (es)
JP (1) JP4536922B2 (es)
KR (1) KR100661769B1 (es)
AT (1) ATE226076T1 (es)
AU (1) AU748883B2 (es)
BR (1) BR9911422A (es)
CA (1) CA2335280C (es)
CZ (1) CZ300844B6 (es)
DE (1) DE69903546T2 (es)
DK (1) DK1089737T3 (es)
EA (1) EA003055B1 (es)
EE (1) EE04355B1 (es)
ES (1) ES2186375T3 (es)
FI (1) FI981473A (es)
HU (1) HU226021B1 (es)
MX (1) MXPA00012618A (es)
NO (1) NO317593B1 (es)
NZ (1) NZ508833A (es)
PL (1) PL193055B1 (es)
PT (1) PT1089737E (es)
SK (1) SK284581B6 (es)
WO (1) WO1999066912A2 (es)
ZA (1) ZA200007462B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20001542A (fi) * 2000-06-29 2001-12-30 Orion Yhtymae Oyj Menetelmä septisen sokin hoitamiseksi
FI20002755A0 (fi) 2000-12-15 2000-12-15 Orion Yhtymae Oyj Menetelmä erektiilin dysfunktion hoitamiseen
FI20010233A0 (fi) 2001-02-08 2001-02-08 Orion Corp Menetelmä sydämen vajaatoiminnan hoitoon
FI20040675A0 (fi) * 2004-05-12 2004-05-12 Orion Corp Menetelmä sydämen hypertrofian hoitoon ja estoon
WO2006087420A2 (en) * 2005-02-18 2006-08-24 Orion Corporation A method for treating heart failure
CA3161960A1 (en) 2019-12-16 2021-06-24 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0302595B1 (en) * 1987-07-07 1994-02-02 Beecham Group Plc Pinacidil for treatment of pulmonary hypertension or right heart failure
GB2251615B (en) * 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
RO113612B1 (ro) * 1991-04-17 1998-09-30 Merck & Co Inc Compozitie oftalmica
GB2266841A (en) 1992-05-06 1993-11-17 Orion Yhtymae Oy Compounds for use as anti-ischemic medicaments
GB9614098D0 (en) * 1996-07-05 1996-09-04 Orion Yhtymae Oy Transdermal delivery of levosimendan

Also Published As

Publication number Publication date
EE200000775A (et) 2002-04-15
NO317593B1 (no) 2004-11-15
JP2002518436A (ja) 2002-06-25
DE69903546T2 (de) 2003-06-18
BR9911422A (pt) 2001-03-13
EA003055B1 (ru) 2002-12-26
AU748883B2 (en) 2002-06-13
ZA200007462B (en) 2002-03-13
CA2335280A1 (en) 1999-12-29
KR20010072640A (ko) 2001-07-31
SK284581B6 (sk) 2005-07-01
DE69903546D1 (de) 2002-11-21
HUP0102929A2 (hu) 2002-04-29
HU226021B1 (en) 2008-03-28
FI981473A (fi) 1999-12-26
DK1089737T3 (da) 2003-02-10
NO20006652D0 (no) 2000-12-22
MXPA00012618A (es) 2005-06-06
FI981473A0 (fi) 1998-06-25
PL193055B1 (pl) 2007-01-31
EE04355B1 (et) 2004-10-15
NZ508833A (en) 2002-10-25
PL345467A1 (en) 2001-12-17
US6462045B1 (en) 2002-10-08
ATE226076T1 (de) 2002-11-15
CA2335280C (en) 2007-10-30
SK19252000A3 (sk) 2002-04-04
HUP0102929A3 (en) 2002-07-29
EA200100074A1 (ru) 2001-06-25
JP4536922B2 (ja) 2010-09-01
NO20006652L (no) 2000-12-22
EP1089737B1 (en) 2002-10-16
KR100661769B1 (ko) 2006-12-28
EP1089737A2 (en) 2001-04-11
AU4786499A (en) 2000-01-10
CZ20004663A3 (en) 2001-05-16
WO1999066912A2 (en) 1999-12-29
PT1089737E (pt) 2003-03-31
WO1999066912A3 (en) 2000-03-16
CZ300844B6 (cs) 2009-08-26

Similar Documents

Publication Publication Date Title
RS50876B (sr) Upotreba flibanserina u lečenju seksualnih poremećaja
DE69326776T2 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
BRPI0114870B8 (pt) uso de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-amino)fenil]-benzamida para a fabricação de composições farmacêuticas para tratamento de tumores estromais gastrointestinais
DE69713151D1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
UA35584C2 (uk) Лікарський засіб для лікування або профілактики ішемії міокарда та спосіб лікування ішемії міокарда у ссавців
ES2185660T3 (es) Nuevo uso de dexmedetomidina.
SE9802208D0 (sv) Novel compounds
ATE206910T1 (de) Levosimendan enthaltende transdermale zusammensetzung
DE59308848D1 (de) Anwendung von urodilatin bei lungen- und bronchialerkrankungen
DE69935853D1 (de) Anwendung von alfa1beta1 integrinrezeptorinhibitoren und tgf-beta1-inhibitoren zur behandlung von nierenkrankheiten
ES2186375T3 (es) Levosimendano para tratar el hipertension pulmonar.
RS50148B (sr) Upotreba docetaksela za lečenje hepatoćelijskog karcinoma
RU2002118304A (ru) Способ подавления чувства страха
CA2427814A1 (en) A combination of a pde4 inhibitor and a leukotriene antagonist in the treatment of bronchial and respiratory disorders
WO2004018044A3 (en) N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-'1,3,4-oxadiazol-2-yl!phenyl)pyridine-3 sulphonamide as an anticancer agent
TR199700735T1 (xx) �ste�e g�re azt,DD1 ya da DDC ile birlikte ters transkritaz inhibit�r� 3T ve HIV proteaz inhibit�r� indinavirin kullan�lmas�yla HIV enfeksiyoun i�in bir arada terapi.
NO20032006D0 (no) Anvendelse av melagatran for fremstilling av et medikament for behandling av ischemiske lidelser
RS51316B (sr) Nova upotreba (r)-(-)-2-/5-(4-fluorofenil)-3- piridilmetilaminometil/-hromana i njegovih fiziološki prihvatljivih soli
CA2363973A1 (en) Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
EA200001098A1 (ru) Пероральные композиции с контролируемым высвобождением левозимендана
DE60009315D1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
SE9802538D0 (sv) New pharmaceutically active compounds
NO20012777L (no) Anvendelse av riluzol ved behandling av akustiske traumer
HUP0202085A2 (hu) Levosimendan alkalmazása koszorúér beültetési vasospasmus kezelésére vagy megelőzésére szolgáló gyógyszerkészítmény előállítására
DE60016038D1 (de) Neue verwendung von levosimendan